Rapcabtagene autoleucel
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
Conditions
Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
Trial Timeline
Jun 20, 2025 → Nov 1, 2028
NCT ID
NCT07048197About Rapcabtagene autoleucel
Rapcabtagene autoleucel is a phase 1/2 stage product being developed by Novartis for Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07048197. Target conditions include Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD).
What happened to similar drugs?
20 of 20 similar drugs in Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD) were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07048197 | Phase 1/2 | Recruiting |
| NCT06665256 | Phase 2 | Recruiting |
| NCT06581198 | Phase 2 | Recruiting |
Competing Products
20 competing products in Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)